INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market saleVerified data
GM

Gold Alexander M sold MLYS

Director · Mineralys Therapeutics, Inc. · Common Stock

Side
SELL
Value
$235K
Shares
5,000
Price
$47.08
Executed
Nov 11, 2025
Disclosed
Nov 13, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 11 executedNov 13, 2025 disclosed

MLYS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
51/ 100 · NOTABLE
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+16 / 25

    $235K reported value · 100.0% of prior position

Filing timing0 / 15

Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+15 / 15

    4 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MLYS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    PK
    Peterson KristineDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    A—
    16.6K sh
    Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    +1dSEC FORM 4

    Evidence

    9
    CL
    Coats LonnelDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    A—
    16.6K sh
    Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    +1dSEC FORM 4

    Evidence

    9
    CL
    Coats LonnelDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    A—
    12.4K sh
    Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    +1dSEC FORM 4

    Evidence

    9
    PK
    Peterson KristineDirector
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    A—
    12.4K sh
    Oct 19, 2026Oct 20, 2026
    traded Oct 19, 2026
    +1dSEC FORM 4

    Evidence

    31
    ST
    Slingsby Brian TaylorDirector
    MLYSMineralys Therapeutics, Inc.
    Open-market sale
    SELL$3.01M
    104.3K sh
    Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    +2dSEC FORM 4

    Evidence

    0
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    M—
    7,438 sh
    Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    +1dSEC FORM 4

    Evidence

    13
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$209K
    7,438 sh
    Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    +1dSEC FORM 4

    Evidence

    2
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    M$98K
    7,438 sh
    Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    +1dSEC FORM 4

    Evidence

    2
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    M$98K
    7,437 sh
    Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    +4dSEC FORM 4

    Evidence

    0
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    M—
    7,437 sh
    Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    +4dSEC FORM 4

    Evidence

    13
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$193K
    7,437 sh
    Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    +4dSEC FORM 4

    Evidence

    9
    FJ
    Ferguson James J. IIIChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    A—
    102.4K sh
    Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    +2dSEC FORM 4

    Evidence

    6
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$59K
    2,170 sh
    Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    +2dSEC FORM 4

    Evidence

    0
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    M—
    2,170 sh
    Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    +2dSEC FORM 4

    Evidence

    0
    RM
    Rodman David MalcomChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    M$35K
    2,170 sh
    Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    +2dSEC FORM 4

    Evidence

    9
    FJ
    Ferguson James J. IIIChief Medical Officer
    MLYSMineralys Therapeutics, Inc.
    Grant or award
    A—
    135.0K sh
    Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    +2dSEC FORM 4

    Evidence

    19
    CJ
    Congleton JonDirector, Chief Executive Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$456K
    17.0K sh
    Jun 30, 2026Jun 30, 2026
    traded Jun 30, 2026
    +0dSEC FORM 4

    Evidence

    11
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    M—
    104.1K sh
    Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    +4dSEC FORM 4

    Evidence

    41
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$2.70M
    104.1K sh
    Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    +4dSEC FORM 4

    Evidence

    20
    WE
    Warren EricChief Commercial Officer
    MLYSMineralys Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    M$1.38M
    104.1K sh
    Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    +4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001933414-25-000149
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 11, 2025
    Published
    Nov 13, 2025
    Ingested by INSIDER
    Nov 5, 04:33 UTC
    Last re-read
    Nov 5, 04:33 UTC

    Extracted facts

    Filer
    Gold Alexander M
    Role
    Director
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Mineralys Therapeutics, Inc.
    Ticker
    MLYS
    Shares
    5,000
    Price per share
    $47.08
    Value
    $235,408
    Execution date (reported)
    Nov 11, 2025
    Owned after transaction
    0 shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 5,000
    • Price: $47.0816

    = $235,408

    What this establishes

    Gold Alexander M filed this Form 4 reporting a open-market sale of MLYS on Nov 11, 2025. It became public on Nov 13, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Gold Alexander Mcik:0002026429
    Issuer
    Mineralys Therapeutics, Inc.cik:0001933414

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.